ArticleACS omega2026
Fluorescent Carbon Dots-Antibiotic Nanocomposite Drug for the Eradication of Multidrug-Resistant Bacteria.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hospital-acquired infections are a growing concern for healthcare providers worldwide. Recently, attention has been devoted to new and emerging nanoparticle-based materials that can help antibiotics destroy multidrug-resistant bacteria. In this work, we conjugated two commercial antibiotics, ampicillin or chloramphenicol, with carbon dots (CDs), forming novel nanoantibiotic-CDs nanocomposites in order to enhance their activity against multidrug-resistant bacteria. These CDs-antibiotics composites were about 4-7 nm in size and were prepared by sonication of poly-(ethylene glycol) (PEG)-400 and the antibiotic drug without using a catalyst. The antibacterial activity of the composites was tested and showed a 4-fold effect in the case of chloramphenicol and at least a 2-fold effect in the case of ampicillin, as compared to the unbound drugs. This method may provide a simple strategy to bring back the use of antibiotics that are no longer clinically relevant due to the increase in antibiotic resistance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.